Dyne Therapeutics, a Waltham, Mass.-based biotechnology company focused on developing life-transforming therapies for patients with serious muscle diseases, closed a $115m equity financing.
The round was led by new investors Vida Ventures and Surveyor Capital (a Citadel company) with participation from new investors Wellington Management Company, Logos Capital, Franklin Templeton and an undisclosed institutional investor and existing investors Atlas Venture, Forbion and MPM Capital.
The company intends to use the funds to accelerate the development of its pipeline of muscle disease therapies, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD), as well as additional indications, including cardiac and metabolic muscle diseases.
Led by Joshua Brumm, president and chief executive officer, Dyne Therapeutics is focused on advancing a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).
FinSMEs
10/08/2020